Impact of Hospital Procedural Volume on Outcomes After Endovascular Revascularization for Critical Limb Ischemia.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
13 09 2021
Historique:
received: 15 04 2021
revised: 22 06 2021
accepted: 29 06 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 3 11 2021
Statut: ppublish

Résumé

The aim of this study was to evaluate the interaction between hospital endovascular lower extremity revascularization (eLER) volume and outcomes after eLER for critical limb ischemia (CLI). There is a paucity of data on the relationship between hospital procedural volume and outcomes of eLER for CLI. The authors queried the Nationwide Readmission Database (2013-2015) for hospitalized patients who underwent eLER for CLI. Hospitals were divided into tertiles according to annual eLER volume: low volume (<100 eLER procedures), moderate volume (100-550 eLER procedures), and high volume (>550 eLER procedures). Stepwise multivariable regression models were used. The main outcomes were in-hospital mortality and 30-day readmission with major adverse limb events, defined as the composite of amputation, acute limb ischemia, or repeat revascularization. Among 145,785 hospitalizations for eLER for CLI, 5,199 (3.6%) were at low-volume eLER hospitals, 27,857 (19.1%) at moderate-volume eLER hospitals, and 112,728 (77.3%) at high-volume eLER hospitals. On multivariable analysis, there was no difference with regard to in-hospital mortality among moderate-volume hospitals (adjusted odds ratio [OR]: 0.78; 95% CI: 0.60-1.01) and high-volume hospitals (adjusted OR: 0.84; 95% CI: 0.64-1.05) compared with low-volume hospitals. There was lower risk of in-hospital major amputation (adjusted OR: 0.82; 95% CI: 0.70-0.96) and minor amputation at high- versus low-volume hospitals. The length of hospital stay was shorter and discharges to nursing facilities were fewer among moderate- and high-volume hospitals compared with low-volume hospitals. Compared with low-volume hospitals, eLER for CLI at high-volume hospitals had a lower risk for 30-day readmission with major adverse limb events (adjusted OR: 0.83; 95% CI: 0.70-0.99), while there was no difference among moderate-volume hospitals (adjusted OR: 0.92; 95% CI: 0.77-1.10). This nationwide observational analysis suggests that annual eLER volume does not influence in-hospital mortality after eLER for CLI. However, high eLER volume (>550 eLER procedures) was associated with better rates of limb preservation after eLER for CLI.

Sections du résumé

OBJECTIVES
The aim of this study was to evaluate the interaction between hospital endovascular lower extremity revascularization (eLER) volume and outcomes after eLER for critical limb ischemia (CLI).
BACKGROUND
There is a paucity of data on the relationship between hospital procedural volume and outcomes of eLER for CLI.
METHODS
The authors queried the Nationwide Readmission Database (2013-2015) for hospitalized patients who underwent eLER for CLI. Hospitals were divided into tertiles according to annual eLER volume: low volume (<100 eLER procedures), moderate volume (100-550 eLER procedures), and high volume (>550 eLER procedures). Stepwise multivariable regression models were used. The main outcomes were in-hospital mortality and 30-day readmission with major adverse limb events, defined as the composite of amputation, acute limb ischemia, or repeat revascularization.
RESULTS
Among 145,785 hospitalizations for eLER for CLI, 5,199 (3.6%) were at low-volume eLER hospitals, 27,857 (19.1%) at moderate-volume eLER hospitals, and 112,728 (77.3%) at high-volume eLER hospitals. On multivariable analysis, there was no difference with regard to in-hospital mortality among moderate-volume hospitals (adjusted odds ratio [OR]: 0.78; 95% CI: 0.60-1.01) and high-volume hospitals (adjusted OR: 0.84; 95% CI: 0.64-1.05) compared with low-volume hospitals. There was lower risk of in-hospital major amputation (adjusted OR: 0.82; 95% CI: 0.70-0.96) and minor amputation at high- versus low-volume hospitals. The length of hospital stay was shorter and discharges to nursing facilities were fewer among moderate- and high-volume hospitals compared with low-volume hospitals. Compared with low-volume hospitals, eLER for CLI at high-volume hospitals had a lower risk for 30-day readmission with major adverse limb events (adjusted OR: 0.83; 95% CI: 0.70-0.99), while there was no difference among moderate-volume hospitals (adjusted OR: 0.92; 95% CI: 0.77-1.10).
CONCLUSIONS
This nationwide observational analysis suggests that annual eLER volume does not influence in-hospital mortality after eLER for CLI. However, high eLER volume (>550 eLER procedures) was associated with better rates of limb preservation after eLER for CLI.

Identifiants

pubmed: 34503743
pii: S1936-8798(21)01232-2
doi: 10.1016/j.jcin.2021.06.032
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1926-1936

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Brilakis has received consulting and speaker honoraria from Abbott Vascular, the American Heart Association (associate editor, Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, the Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, and GE. Dr Drachman is a consultant to Abbott Vascular, Boston Scientific, Broadview Ventures, and Cardiovascular Systems. Dr. Elgendy has disclosures unrelated to this manuscript content including receiving research grants from Caladrius Biosciences, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Ayman Elbadawi (A)

Division of Cardiology, Baylor College of Medicine, Houston, Texas, USA.

Islam Y Elgendy (IY)

Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar.

Devesh Rai (D)

Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA.

Dhruv Mahtta (D)

Division of Cardiology, Baylor College of Medicine, Houston, Texas, USA.

Michael Megaly (M)

Division of Cardiology, Banner University Medical Center, Phoenix, Arizona, USA.

Ashish Pershad (A)

Division of Cardiology, Chandler Regional Medical Center, Chandler, Arizona, USA.

Ali Denktas (A)

Division of Cardiology, Baylor College of Medicine, Houston, Texas, USA.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute at Abbott Northwestern Hospital and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Douglas E Drachman (DE)

Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Subhash Banerjee (S)

Division of Cardiology, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.

Mehdi H Shishehbor (MH)

Heart and Vascular Institute, University Hospitals, and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Hani Jneid (H)

Division of Cardiology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: jneid@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH